Cisplatin ototoxicity involves cytokines and STAT6 signaling network

Area of Science:

• Molecular Biology
• Immunology
• Ototoxicity Research

Background:

• Cisplatin is a widely used chemotherapy agent with known ototoxic side effects.
• The role of the STAT signaling pathway in cisplatin-induced ototoxicity and inflammation remains incompletely understood.

Purpose of the Study:

• To investigate the involvement of the STAT signaling cascade in pro-inflammatory cytokine production and cisplatin-induced ototoxicity.
• To elucidate the specific role of STAT6 in the cellular response to cisplatin.

Main Methods:

• Utilized wild-type (WT), STAT4(-/-), and STAT6(-/-) mice models to assess hearing impairment and cytokine levels post-cisplatin treatment.
• Performed organotypic cultures of cochlear tissues to evaluate hair cell integrity.
• Investigated STAT6 phosphorylation and cellular responses in HEI-OC1 auditory cells treated with cisplatin, including STAT6 knockdown via siRNA.

Main Results:

• STAT6(-/-) mice showed significantly less hearing impairment and preserved cochlear hair cell structures compared to WT and STAT4(-/-) mice after cisplatin exposure.
• Pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6) were elevated in WT and STAT4(-/-) mice but not in STAT6(-/-) mice.
• Cisplatin induced STAT6 phosphorylation in auditory cells; STAT6 knockdown protected cells from cisplatin-induced death and reduced cytokine production.

Conclusions:

• STAT6 signaling is crucial in mitigating cisplatin-induced ototoxicity and suppressing pro-inflammatory cytokine production.
• STAT6 activation, potentially modulated by IL-4 and IL-13, plays a protective role against cisplatin's damaging effects on the auditory system.